文献速递胸部肿瘤放疗放疗物理与技术

肺癌高危患者风险适应剂量优化食管保护放疗的可行性与毒性

A risk-adapted, dose-optimized esophagus-sparing radiation therapy technique for high-risk patients with lung cancer: feasibility, dosimetry, and acute esophageal toxicity.
PubMed 文献 · Radiat Oncol · 2026-06-23

本研究纳入80例接受根治性胸部放疗的肺癌高危患者,食管与临床靶区距离≤5mm,采用风险适应、剂量优化的节段性食管保护策略。结果显示急性放射性食管炎发生率为30.0%,仅1例3级、无≥4级毒性;历史对照任何级别ARI E发生率为76.5%。配对剂量学比较显示该策略降低食管受量并较好保持靶区覆盖。

要点

  • 食管保护策略使高危肺癌患者急性食管炎发生率降至30.0%,仅1例3级毒性。
  • 根据PTV与中央损伤有效食管重叠程度分段限制食管保护区平均剂量。
  • 配对剂量学比较显示食管受量降低且靶区覆盖基本保持。

核心结论

  • 风险适应、剂量优化的节段性食管保护策略在肺癌高危患者中可行,可能减少临床相关急性放射性食管炎并较好保持靶区覆盖,尚需前瞻性验证。

研究设计与样本

  • 单中心研究,纳入2023年5月至2025年1月接受根治性胸部放疗的80例肺癌患者,食管位于临床靶区5mm以内。
  • 损伤有效食管定义为中央损伤有效食管加上下各2cm外扩,中央损伤有效食管涵盖PTV与食管重叠的所有轴位层面。
  • 根据PTV与中央损伤有效食管重叠程度(<1/3、1/3-2/3、>2/3)将食管保护区平均剂量分别限制为处方剂量的1/3、1/2、2/3。
  • 急性放射性食管炎采用RTOG标准分级,并进行10例配对剂量学比较。

主要发现

  • 80例患者中急性放射性食管炎发生24例(30.0%),仅1例3级,无≥4级毒性。
  • 历史对照队列任何级别急性放射性食管炎发生率为76.5%。
  • 10例配对剂量学比较显示食管保护策略降低食管剂量暴露,尤其食管保护区内,同时较好保持靶区覆盖并维持可接受的危及器官约束。
  • 探索性单变量分析提示急性放射性食管炎与同步化疗-免疫-放疗、食管保护区几何范围、较高食管剂量暴露及食管保护计划未通过相关。
  • 生存结果仅作描述性报告。

关键数值与推荐

  • 食管保护区平均剂量限制:PTV与中央损伤有效食管重叠<1/3时限制为处方剂量1/3,1/3-2/3时限制为1/2,>2/3时限制为2/3。

临床怎么用

  • 对食管紧邻靶区的肺癌高危放疗患者,可按PTV与中央损伤有效食管重叠程度分段限制食管保护区的平均剂量。
  • 该策略在降低急性放射性食管炎的同时需确保靶区覆盖和危及器官约束可接受。

局限性

  • 生存结果仅作描述性报告,非主要终点。
  • 急性放射性食管炎与相关因素的关联来自探索性单变量分析。
  • 研究为单中心设计,尚需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute radiation-induced esophagitis (ARIE) remains a clinically significant toxicity during definitive thoracic radiation therapy (TRT), particularly in patients with close esophagus-planning target volume (PTV) proximity. This study evaluated a risk-adapted, dose-optimized esophagus-sparing (ES) strategy designed to reduce ARIE while maintaining adequate target coverage in high-risk patients. METHODS: Eighty patients with lung cancer treated with definitive TRT between May 2023 and January 2025 were enrolled. The injury-effective esophagus (IEE) was defined as the local high-risk esophageal segment consisting of the central-IEE and an additional 2-cm superior and inferior cranio-caudal expansion. The central-IEE encompassed all axial levels where PTV-esophagus overlap was present, and the ES region was contoured as the portion of the IEE outside the PTV. Based on the degree of PTV/central-IEE overlap (< 1/3, 1/3-2/3, > 2/3), the ES mean dose was constrained to 1/3, 1/2, and 2/3 of the prescribed dose, respectively. ARIE was graded using Radiation Therapy Oncology Group (RTOG) criteria. Progression-free survival (PFS) was defined from initiation of the TRT to progression or death; overall survival (OS) was also evaluated. RESULTS: Among 80 high-risk patients with the esophagus located within 5 mm of the clinical target volume (CTV), ARIE occurred in 24 patients (30.0%), including only one Grade 3 event and no Grade ≥ 4 toxicity. For contextual reference, the incidence of any-grade ARIE in a pre-ES historical benchmark cohort was 76.5%. In a paired dosimetric comparison of 10 cases, the ES strategy reduced esophageal dose exposure, particularly within the ES region, while substantially preserving target coverage and maintaining acceptable organ at risk (OAR) constraints. Exploratory univariable analyses suggested associations between ARIE and concurrent chemo-immuno-radiation therapy (CIRT), the geometric extent of the ES region, higher esophageal dose exposure, and failure to pass the ES-plan. Survival outcomes were descriptive only. CONCLUSIONS: This risk-adapted, dose-optimized segmental ES strategy appears feasible and may reduce clinically relevant ARIE with broadly preserved target coverage. Prospective validation is warranted.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Huang JQ, Li SY, Li H, et al. A risk-adapted, dose-optimized esophagus-sparing radiation therapy technique for high-risk patients with lung cancer: feasibility, dosimetry, and acute esophageal toxicity. Radiat Oncol. 2026. PMID: 42337559. doi:10.1186/s13014-026-02880-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。